You are here

Article Text

Article menu
PDF
Electronic pages
Letter
Patients with non-Jo-1 anti-RNA-synthetase autoantibodies have worse survival than Jo-1 positive patients
  1. Baptiste Hervier1,
  2. Hervé Devilliers2,
  3. Olivier Benveniste3
  1. 1Internal Medicine department 2, French Reference Centre for Lupus; Hôpital Pitié-Salpêtrière, APHP & University of Paris VI Pierre & Marie Curie, Paris, France
  2. 2Clinical Investigation Centre, Clinical Epidemiology & Clinical Trials, INSERM CIE1 and Internal Medicine & Systemic Disease Department, University Hospital of Dijon, Dijon, France
  3. 3Internal Medicine department 1, French Reference Centre for Neuromuscular Disorders; Hôpital Pitié-Salpêtrière, APHP & University of Paris VI Pierre & Marie Curie, Paris, France
  1. Correspondence to Dr Baptiste Hervier, Service de Médecine Interne 2, Centre National de référence du Lupus, 47-83 boulevard de l'hôpital, Paris, cedex 13 75651, France; bhervier{at}yahoo.fr

http://dx.doi.org/10.1136/annrheumdis-2013-203605

Statistics from Altmetric.com

    We read with interest the manuscript by Aggarwal et al1 entitled ‘Patients with non-Jo-1 anti-RNA-synthetase autoantibodies have worse survival than Jo-1 positive patients’. This large cohort study provides important information on outcomes for patients with antisynthetase syndrome (ASS), based on the specificity of the anti-RNA-synthetase autoantibody subtypes. Interestingly, the authors decided to include patients with anti-glycyl (EJ), anti-isoleucyl (OJ) and anti-asparagyl (KS)-tRNA-synthetase autoantibodies, something which had not yet been done in the previous studies,2 ,3 due to …

    View Full Text

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions